1[1]Silver RT,Woolf SH,Hehlmann R,et al.An evidence-based analysis of effect of busulfan,hydroxyurea,interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia:developed for the American Society of Hematology.Blood 1999; 94:1517～ 1536
2[2]Faderl S,Talpaz M,Estrov Z,et al.Chronic myelogenous leukemia:Biology and therapy.Ann Intern Med 1999;131:207～209
3[3]Goldman Jm,Szydlo R,Horowitz MM,et al.Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase.Blood 1993; 82:2235～ 2238
4[4]Chronic Myeloid Leukemia trialists/collaborative group:Interferon alfa versus chemotherapy for chronic myeloid leukemia:A metaanalysis of seven randomized trials.J Nat Cancer Inst 1997; 89:1616
5[5]O' Brien S,Kartarjian H,Koller C,et al.Sequential homoharringtonine and interferon-α in the treatment of early chronic phase chronic myelogenous leukemia.Blood 1999; 93:4149～ 4153
6[6]Kantarjian HM,O' Brien SM,Keating M,et al.Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.Leukemia 1997; 11:1617～ 1620
7[7]Talpaz M,Cortes J,O' Brien S,et al.Phase I study of polyethylene glycol(PEG) interferon alpha-2b(Intron-A) in chronic patients.Blood 1998;92(Sup1):251
8[8]Maran A,Waller CF,Paranjape JM,et al.2',5'-0 ligoadenylateantisense chimeras cause RNase L to selectively degrade bcr/ab1 mRNA in chronic myelogenous leukemia cells.Blood 1998; 92:4336～4343
9[9]Druker BJ,Sawyers CL,Talpaz M,et al.Phase Ⅰ trial of a specific ABL tyrosine kinase inhibitor,CGP 57148,in interferon refractory chronic myelogenous leukemia patients.Proceedings of the American Society of Clinical Oncology 1999; 18:72
